Published in final edited form as:

Neurosci Lett. 2006 December 13; 410(1): 11–14.

Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor

Kayla C. De Lorme, Krista L. Sikorski, Marianne K. O. Grant, and Esam E. El-Fakahany

Division of Neuroscience Research in Psychiatry, University of Minnesota Medical School, Mayo Mail Code 392, 420 Delaware St. SE, Minneapolis, MN 55455 USA

Abstract

Compared to other M₁ muscarinic acetylcholine receptor (M₁ mAChR) agonists, xanomeline demonstrates both reversible and persistent modes of binding to the receptor. In our study, we investigated the long-term consequences of brief incubation of Chinese hamster ovary cells expressing M₁ mAChR (M₁-CHO) with low concentrations of xanomeline followed by washing off the free drug. Thus, M₁-CHO cells were exposed to 100 nM xanomeline for 1 h then washed extensively. Washed cells were either used immediately for binding assays or incubated for 23 h in the absence of free xanomeline. Only the latter treatment conditions resulted in marked attenuation of binding of the muscarinic radioligand [³H]N-methylscopolamine ([³H]NMS) to intact cells. Shortening the xanomeline pretreatment period to 1 min had the same trends as the 1 h pretreatment, implying that xanomeline binds instantly to the receptor to elicit long-term wash-resistant effects. Presence of atropine during the brief period of xanomeline pretreatment did not markedly modulate xanomeline's long-term effects, which suggests that persistent anchoring of the xanomeline molecule to the M₁ receptor takes place at a site distinct from the orthosteric binding domain. Our findings suggest the possibility of a time-dependent transition of the conformation of the muscarinic M₁ receptor-xanomeline complex between states that vary in their ability to bind [³H]NMS. However, possible involvement of other mechanisms of long-term receptor regulation cannot be discounted.

Keywords

xanomeline; wash-resistant binding; muscarinic receptors; allosteric modulation

The muscarinic acetylcholine receptor family consists of five receptor subtypes (M₁-M₅) and is part of the superfamily of G-protein coupled receptors [6]. Targeting the M₁ muscarinic acetylcholine receptor (M₁ mAChR) has become of interest due to its role in learning and memory, and the potential it may have in treating certain neurodegenerative diseases [10]. The search for a selective M₁ agonist is necessary to prevent activation of other subtypes such as the M₃, which is responsible for many of the gastrointestinal side effects seen in acetylcholine replacement therapies. Because the orthosteric binding domain on muscarinic receptors where acetylcholine and conventional agonists interact is highly conserved among the five muscarinic receptor subtypes, developing a highly selective M₁ mAChR agonist has been difficult. However, multiple allosteric binding sites have been identified on the M₁ mAChR [4]. Being

Corresponding Author: Prof. Esam E. El-Fakahany Neuroscience Research in Psychiatry University of Minnesota Medical School Mayo Mail Code 392 420 Delaware St. SE Minneapolis, MN 55455 Phone: +612 624 8432 Fax: +612 624 8935 email: elfak001@umn.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

distant from the primary binding site, they likely vary in sequence among receptor subtypes [1,4] and may serve as targets for binding of M₁ mAChR-selective agonists [12].

Xanomeline is a potent, functionally selective M₁ mAChR agonist [11]. Previous studies have demonstrated that it displays a unique mode of binding to the M₁ mAChR as compared to other agonists. In addition to its reversible interaction with the classical orthosteric binding site of the M₁ mAChR, xanomeline also binds persistently to a secondary site(s) on the receptor [2, 3]. This wash-resistant binding occurs almost instantaneously at the M₁, but not the M₂ mAChR [7], which suggests induction of receptor subtype-specific conformations by xanomeline. This receptor subtype selectivity and the lack of similar effects when liposomes are treated with xanomeline prior to reconstitution of M1 receptors [8] support a receptor specific mechanism. These findings also strongly argue against the possibility of membrane lipids serving as a non-specific depot of xanomeline where xanomeline leeches out to rebind to the receptor causing persistent activation. It has been shown that persistent xanomeline binding to the M₁ mAChR acutely modulates binding of ligands to the orthosteric site in an allosteric manner [2,7,9]. It also causes wash-resistant receptor activation that is silenced by atropine [2]. However, long-term consequences of xanomeline's persistent interaction with the M₁ mAChR are not known.

In the current study, we examined the long-term effects of brief exposure of the M₁ mAChR to low concentrations of xanomeline. Chinese hamster ovary cells, stably expressing the human M₁ mAChR (M₁-CHO), were grown at 37°C in Dulbecco's modified Eagle's medium, supplemented with 10% bovine calf serum and 50 µg/ml geneticin, in a humidified atmosphere consisting of 5% CO₂ and 95% air. M₁-CHO cells were pretreated in monolayer in the absence or in the presence of 100 nM xanomeline at 37°C. After short incubation times (1 h or 1 min), cells were washed three times to remove unbound xanomeline with iso-osmotic HEPES buffer (110 mM NaCl, 5.3 mM KCl, 1.8 mM CaCl₂, 1 mM MgCl₂, 25 mM glucose, 20 mM HEPES, and 58 mM sucrose, pH 7.4; 340 mOsm). Cells were then used immediately in binding assays or allowed to incubate in monolayer in the absence of free xanomeline for a long period of time (23 or 24 h at 37°C, in the case of 1 h or 1 min pretreatment with xanomeline, respectively). In all cases, cells were washed again three times prior to their use in binding experiments. Further experiments were designed using atropine (10 µM), either during the initial pretreatment period with xanomeline for 1 h, or during the 23 h incubation following washing off free xanomeline. Each experimental group also had respective controls in the absence of xanomeline pretreatment. Binding of [³H]N-methylscopolamine ([³H]NMS) was determined in intact cells (1 h, 37°C) and radioactivity was measured using liquid scintillation counting. Non-specific binding was determined using 10 µM atropine. Results are expressed as mean ± standard error of the mean. Statistical significance was determined by paired or unpaired *t*-tests, as appropriate. A probability (*p*) value < 0.05 was taken to indicate statistical significance.

The binding of 0.2 nM [³H]NMS in intact M₁-CHO cells following the 1 h xanomeline pretreatment conditions is shown in Fig. 1. The continuous presence of 100 nM xanomeline in naïve cells inhibited the binding of [³H]NMS by 34% in comparison to control untreated cells. This experimental group detects the combined effects of both reversible and wash-resistant xanomeline binding. Pretreatment of cells with the same concentration of xanomeline for 1 h followed by washing did not demonstrate significant apparent wash-resistant effects on [³H]NMS binding (Fig. 1, open bar). However, a marked decrease (44%) in radioligand binding compared to vehicle treated cells was observed when pretreated cells were allowed to incubate for an additional 23 h in the absence of free xanomeline (Fig. 1, dark bar). This effect was similar to, albeit smaller than, the effect of continuous incubation of cells with 100 nM xanomeline for 24 h before washout (Fig. 1, striped bar).

In order to further examine the effects of the time dependence of xanomeline, the pretreatment time was drastically reduced from 1 h to 1 min. Surprisingly, very similar effects were seen

following 1 min as compared to 1 h pretreatment conditions. Thus, while [3 H]NMS binding was not reduced by 1 min pretreatment with 100 nM xanomeline followed by washing and immediate use (Fig. 1, open bar) as compared to binding in control untreated cells, a 35% reduction in radioligand binding was observed when pretreated cells were washed and allowed to incubate for an additional 24 h in the absence of free xanomeline (Fig. 1, dark bar).

Additional experiments utilizing the muscarinic antagonist atropine were designed to investigate the mechanisms underlying the long-term effects of prebound xanomeline. Namely, whether xanomeline's initial interaction with the receptor involves sites other than the orthosteric binding site, and whether receptor activation is required for subsequent long-term effects of xanomeline. We have shown previously that blockade of the receptor's primary binding domain by atropine still allows wash-resistant interaction of xanomeline with the M_1 receptor [9]. However, atropine completely blocks receptor activation by prebound xanomeline [2]. Taken together, xanomeline tight binding takes place at a secondary allosteric site on the M_1 muscarinic receptor, but the associated persistent receptor activation requires interaction of xanomeline's active head group with the receptor's primary binding domain. To achieve these goals, atropine was either added at a receptor-saturating concentration (10 μ M) simultaneously with xanomeline during the 1 h pretreatment period, or during the long waiting period in the absence of free xanomeline. The concentration of xanomeline used for pretreatment was increased to 3 μ M in these experiments to maximize xanomeline long-term effects and therefore facilitate observing the effects of atropine. Furthermore, a saturating concentration (6 nM) of [3 H]NMS was chosen to determine changes in maximal binding without interference from alterations in receptor affinity.

As shown in Fig. 2 (open bar), pretreatment of cells with 3 μ M xanomeline for 1 h followed by washing and waiting for 23 h inhibited [3 H]NMS binding by 78% (compared to vehicle treated cells). When cells were pretreated with xanomeline and atropine simultaneously for 1 h, followed by washing and waiting for 23 h in the absence of either drug, the inhibition of [3 H]NMS binding was only slightly reduced to approximately 68% of control binding (Fig. 2, grey bar). Thus, 10% of radioligand binding was recovered when atropine was present during the pretreatment. More evident was the effect of atropine when present only during the 23 h incubation period after xanomeline pretreatment and washing. These conditions completely obliterated the long-term effects of xanomeline prebound to the receptor (Fig 2, dark bar). Control binding was defined as pretreatment in the absence of xanomeline, but in the presence of atropine for the corresponding incubation periods of either 1 or 23 h.

Complete blockade of the orthosteric site by atropine during pretreatment with xanomeline only slightly suppressed the long-term effects of xanomeline. These results are in concert with our previous demonstration of the possible simultaneous interaction of xanomeline (at the allosteric site) and atropine (at the orthosteric site) with the M_1 mAChR [9]. When atropine is washed away, persistently bound xanomeline continues to elicit long-term changes of the receptor. In contrast, the presence of atropine during the long-term incubation period completely abolished the effects of wash-resistant xanomeline on radioligand binding (Fig. 2), suggesting an interaction involving xanomeline's active head group with the receptor's primary binding domain as suggested by our previous findings [2].

One plausible interpretation of our data is that brief incubation with low concentrations of xanomeline results in initial wash-resistant binding at a distinct receptor domain on the muscarinic M_1 receptor to induce a receptor conformation where the orthosteric binding domain is still fully capable of recognizing [3 H]NMS. This initial conformation is then transformed in a time-dependent manner to one that exhibits reduced binding of [3 H]NMS. It is worth noting that very similar effects were seen following 1 min as compared to 1 h pretreatment conditions (Fig. 1), suggesting that induction of the initial xanomeline-receptor

conformation is immediate. Receptor internalization or down-regulation may also explain the delayed large decrease in binding effected by persistently bound xanomeline. There is a large body of evidence suggesting that long-term treatment with agonists can decrease receptor expression or diminish receptor-mediated functional responses [5,13,14]. This notion is supported by the similarity in the effects of prolonged incubation of xanomeline pretreated and washed cells and those of continuous incubation with xanomeline for 24 h (Fig. 1). Detailed future experiments utilizing cell-permeable muscarinic radioligands, Western analysis of receptor expression and broken cell preparations are required to differentiate among these mechanistic possibilities.

In this study we have clearly shown that very brief exposure of M₁-CHO cells to low concentrations of xanomeline that do not cause immediate wash-resistant effects on ligand binding results in long-term effects on the M₁ mAChR. These effects are time-dependent and involve binding of xanomeline at a secondary allosteric domain on the receptor. Future research is planned to determine the molecular mechanisms involved in this phenomenon.

Acknowledgements

This work was supported by NIH grant NS25743.

References

- [1]. Bonner TI, Modi WS, Seunanez HN, O'Brien SJ. Chromosomal mapping of the five human genes encoding muscarinic acetylcholine receptors. *Cytogenet. Cell Genet* 1991;58:1850–1851.
- [2]. Christopoulos A, Pierce TL, Sorman JL, El-Fakahany EE. On the unique binding and activation properties of xanomeline at M₁ muscarinic acetylcholine receptor. *Mol. Pharmacol* 1998;53:1120–1130. [PubMed: 9614217]
- [3]. Christopoulos A, El-Fakahany EE. Novel persistent activation of muscarinic M₁ receptors by xanomeline. *Eur. J. Pharmacol* 1997;334:R3–R4. [PubMed: 9346340]
- [4]. Espinoza-Fonseca LM, Trujillo-Ferrara JG. The existence of a second allosteric site on the M₁ muscarinic acetylcholine receptor and its implications for drug design. *Bioorg. Med. Chem. Lett* 2006;16:1217–1220. [PubMed: 16364641]
- [5]. Hu J, Wang SZ, El-Fakahany EE. Effects of agonist efficacy on desensitization of phosphoinositide hydrolysis mediated by m1 and m3 muscarinic receptors expressed in Chinese hamster ovary cells. *J. Pharmacol. Exp. Ther* 1991;257:938–945. [PubMed: 1710663]
- [6]. Hulme EC, Birdsall NJM, Buckley NJ. Muscarinic receptor subtypes. *Ann. Rev. Pharmacol. Toxicol* 1990;30:633–673. [PubMed: 2188581]
- [7]. Jakubík J, El-Fakahany EE, Dolezal V. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at the M₁ and M₂ muscarinic acetylcholine receptor. *Mol. Pharmacol* 2006;70:656–666. [PubMed: 16675658]
- [8]. Jakubík J, Tuček S, El-Fakahany EE. Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to the muscarinic M₁ receptors. *J. Pharmacol. Exp. Ther* 2004;308:105–110. [PubMed: 14569060]
- [9]. Jakubík J, Tuček S, El-Fakahany EE. Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M₁ muscarinic acetylcholine receptor. *J. Pharmacol. Exp. Ther* 2002;301:1033–1041. [PubMed: 12023535]
- [10]. McKinney M, Coyle JT. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease. *Mayo Clin. Proc* 1991;66:225–237.
- [11]. Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ, et al. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M₁ receptors. *J. Pharmacol Exp. Ther* 1994;269:1297–1302.
- [12]. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR. Discovery of an ectopic activation site on the M1 muscarinic receptor. *Mol. Pharmacol* 2002;61:1297–1302. [PubMed: 12021390]

- [13]. Walker JK, Gainetdinov RR, Feldman DS, McFawn PK, Caron MG, Lefkowitz RJ, Premont RT, Fisher JT. G protein-coupled receptor kinase 5 regulates airway responses induced by muscarinic receptor activation. *Am. J. Physiol. Lung Cell Mol. Physiol* 2004;286:L312–L319. [PubMed: 14565944]
- [14]. Wang SZ, Hu JR, Long RM, Pou WS, Forray C, El-Fakahany EE. Agonist-induced down-regulation of m1 muscarinic receptors and reduction of their mRNA level in a transfected cell line. *FEBS Lett* 1990;276:185–188. [PubMed: 2265699]

Figure 1.

Effects of xanomeline pretreatment, followed by washout on [^3H]NMS binding in M_1 -CHO cells. Cells were pretreated with 100 nM xanomeline for 1 h or 1 min at 37°C, washed extensively then used immediately in binding assays (open bars) or allowed to incubate in the absence of free xanomeline for 23 h or 24 h (dark bars), respectively. Another group of cells were continuously incubated with 100 nM xanomeline for 24 h followed by washing and immediate determination of [^3H]NMS binding (striped bar). Receptor binding was assayed by incubation of intact cells for 1 h at 37°C with 0.2 nM [^3H]NMS. For each experimental group, control binding was defined as specific [^3H]NMS binding in vehicle-treated cells. When continuously present during the binding assay, 100 nM xanomeline resulted in 34% reduction in radioligand binding in naïve cells. Values represent the means $\pm$ SEM of six to fifteen experiments performed in triplicate. *Paired t -test showed a significant difference ($p < 0.05$) compared to control.

Figure 2.

Effects of atropine on the long-term effects of persistently bound xanomeline. M₁-CHO cells were pretreated for 1 h at 37°C with 3 μ M xanomeline in the absence (open bar) or in the presence (grey bar) of 10 μ M atropine, washed extensively and allowed to incubate for 23 h before determination of [3 H]NMS binding in intact cells (6 nM, 1 h at 37°C). Another group of cells (dark bar) was preincubated with 3 μ M xanomeline for 1 h at 37°C, washed, then incubated with 10 μ M atropine for 23 h. Data were normalized to percent of control binding in the absence of xanomeline, but in the presence of corresponding incubations with atropine for either 1 or 23 h. Bars represent the means $\pm$ SEM of four experiments performed in triplicate. *Paired *t*-test showed a significant difference ($p < 0.05$) compared to each group's respective controls in the absence of xanomeline.